Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.30 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13947101 | 0.93 | PTK2 (0.34) | SCN9APTK2LRRK2 | |
| SCHEMBL13044756 | 0.93 | SCN9A (0.34) | SCN9APTK2KDR | |
| SCHEMBL13044704 | 0.92 | SCN9A (0.35) | SCN9APTK2KDR | |
| SCHEMBL13044744 | 0.92 | SCN9A (0.33) | SCN9APTK2KDR | |
| SCHEMBL13044814 | 0.92 | SCN9A (0.33) | SCN9APTK2KDR | |
| SCHEMBL13044802 | 0.92 | SCN9A (0.33) | SCN9APTK2KDR | |
| SCHEMBL13947023 | 0.91 | SCN9A (0.33) | SCN9APTK2 | |
| SCHEMBL13044816 | 0.91 | SCN9A (0.33) | SCN9APTK2 | |
| SCHEMBL13044748 | 0.90 | SCN9A (0.33) | SCN9APTK2 | |
| SCHEMBL13078552 | 0.90 | SCN9A (0.33) | SCN9APTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286131-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-11 | — | — | US | disclosed |
| WO-2009018656-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286131-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2B | SCN9A 1852/4885PTK2 4679/4885LRRK2 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.